| Literature DB >> 32427361 |
Scott Benkovic1, Michelle Kim1, Eric Sin2.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32427361 PMCID: PMC7276853 DOI: 10.1002/jmv.26029
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 20.693
Clinical characteristics and outcome of four HIV and COVID‐19 coinfection
| Patient | Age/Sex | HIV Diagnosis date | CD4/Viral Load | HIV medication Regimen | Comorbid conditions | Presenting symptoms | Outcome |
|---|---|---|---|---|---|---|---|
| A | 56/Male | 1995 | 1206/54 | Emtricitabine | HLD | Fatigue | Home isolation until recovery |
| Tenofovir AF | Anosmia Aguesia | ||||||
| Dolutegravir | |||||||
| Maraviroc | |||||||
| B | 56/Male | 1988 | 794/<20 | Emtricitabine | HTN | Fever | Home isolation until recovery |
| Tenofovir AF | Fatigue | ||||||
| Etravirine | |||||||
| Abacavir | |||||||
| C | 62/Male | 1996 | 1412/<20 | Emtricitabine | HCV | Fever | Home isolation until recovery |
| Tenofovir AF | HLD | Cough | |||||
| Dolutegravir | HTN | Fatigue | |||||
| Diarrhea | |||||||
| D | 65/Male | 2006 | 929/<20 | Emtricitabine | A. Fib | Cough | Hospitalization for 2 wk |
| Tenofovir AF | HLD | Fever | |||||
| Elvitegravir | HTN | ||||||
| Cobicistat | T2DM |
Abbreviations: AF, alafenamide; A. Fib, atrial fibrillation; CD4 T, cell count measured in cells/µL; HCV, hepatitis C; HLD, hyperlipidemia; HTN, hypertension; T2DM, type II diabetes mellitus.